NCT04432623 - The BENeFiTS Trial in Beta Thalassemia Intermedia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 5, 2020

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions

Beta Thalassemia IntermediaSickle Cell Disease

Interventions

DRUG

Benserazide Only Product

Investigational drug

Trial Locations (5)

Weil Cornell Medicine, New York

UCSF Benioff Children's Hospital at Oakland, Oakland

Massachusetts General Hospital, Boston

Susan Perrine, Weston

University Health Network and Toronto General Hospital, Toronto